Key result
Beta-blockers reduce morbidity and mortality in hypertension and post-MI while improving angina and heart failure symptoms.
Why the study?
Despite established mortality and morbidity benefits after acute myocardial infarction, a presumption of poor tolerance has left beta-blockers underutilized in this clinical setting, and multiple drug-specific factors must be considered when selecting therapy across cardiovascular indications.
Do beta-blockers improve clinical outcomes, mortality, morbidity, and symptoms in patients with hypertension, coronary heart disease, and congestive heart failure?
Do beta-blockers improve clinical outcomes, mortality, morbidity, and symptoms in patients with hypertension, coronary heart disease, and congestive heart failure?
This review highlights the established benefits of beta-blockers across hypertension, angina, post-myocardial infarction, and heart failure, while noting their underutilization due to perceived tolerability concerns.
Answers are grounded in this paper and cite their sources.
Supports beta-blocker use post-MI and in hypertension; Level 5 evidence leaves optimal duration and modern applicability open.
Beta-Blockers are widely used in cardiovascular medicine. In patients with hypertension, beta-blockers show beneficial effects on clinical end points of stroke and coronary heart disease prevention and mortality. beta-blockers also are well established in improving exercise tolerance and decreasing the number and duration of anginal attacks in patients with angina pectoris. Based on evidence showing reduced mortality and morbidity, beta-blockers are the cornerstone of therapy after acute myocardial infarction. Unfortunately, presumption of poor tolerance has left these drugs underutilized in this clinical setting, despite data that indicate a wide range of tolerability. The use of beta-blockers in patients with congestive heart failure results in beneficial hemodynamic effects and symptomatic improvement. Among factors that should be considered when selecting a beta-blocker for an individual patient are demonstrated efficacy of the drug in a specific indication, tolerability, product formulation and duration of action, and the presence or absence of specific properties such as cardioselectivity.
No takes yet. Share an insight, caveat, or question.
S. Goldstein (1996) conducted a review in Hypertension, coronary heart disease (angina pectoris, acute myocardial infarction), and congestive heart failure. Beta-blockers was evaluated on Clinical endpoints including stroke and coronary heart disease prevention, mortality, morbidity, exercise tolerance, anginal attacks, and hemodynamic and symptomatic effects. Beta-blockers reduce mortality and morbidity in hypertension and post-MI, and improve angina and heart failure symptoms, though no specific quantitative data are reported in the abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: